Generic Name and Formulations:
Lisdexamfetamine dimesylate 20mg, 30mg, 40mg, 50mg, 60mg, 70mg; caps.
Shire US, Inc.
Indications for VYVANSE:
Attention deficit hyperactivity disorder.
Adults and Children's Dose:
<6yrs: not established. Individualize. ≥6yrs: 30mg once daily in AM. May adjust in increments of 10mg or 20mg per day at weekly intervals; max 70mg/day. Swallow whole or may dissolve contents of capsule in water, take immediately (do not subdivide caps).
During or within 14 days of MAOIs.
Risk of potential abuse and dependence; monitor. Increased risk of sudden death, stroke, and MI. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Bipolar disorder. Screen for risk factors in developing manic episode prior to initiating. Psychosis. Risk of peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR. Write ℞ for smallest practical amount. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Hypertensive crisis with MAOIs. Potentiated by sodium bicarbonate and other urinary alkalinizing agents. Antagonized by urinary acidifiers (eg, ascorbic acid).
Anorexia, anxiety, decreased appetite/weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, vomiting; hypertension, tachycardia, rash (may be serious).
- 30mg capsules (Qty:30)
- appx. price $212.00